Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2025)

Monte Rosa Therapeutics' FCF Margin history spans 2 years, with the latest figure at 1699.93% for Q4 2025.

  • For Q4 2025, FCF Margin fell 191870.0% year-over-year to 1699.93%; the TTM value through Dec 2025 reached 22.23%, down 7770.0%, while the annual FY2025 figure was 22.23%, 7770.0% down from the prior year.
  • FCF Margin reached 1699.93% in Q4 2025 per GLUE's latest filing, down from 808.83% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 808.83% in Q3 2025 to a low of 3717.01% in Q1 2024.